Anzeige
Mehr »
Mittwoch, 02.07.2025 - Börsentäglich über 12.000 News
Nächster Kursturbo?: 226 % Plus seit Januar - wie weit kann diese Aktie noch steigen?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
370 Leser
Artikel bewerten:
(1)

bioMerieux to Exhibit at SupplySide West 2021 at Mandalay Bay in Las Vegas Oct. 25-28, 2021

bioMérieux to Showcase its Full Suite of Nutraceutical Testing Solutions, Including the Recently Released GENE-UP® NUTRAPLEX PRO Assay

CHICAGO, IL / ACCESSWIRE / October 5, 2021 / bioMérieux, a world leader in the field of?in vitro?diagnostics, will exhibit at SupplySide West 2021, the leading trade show for health and nutrition industry professionals focused on dietary supplements, beverages, functional foods, personal care, and sports nutrition innovation. SupplySide West 2021 will take place at Mandalay Bay Resort And Casino in Las Vegas Oct. 25-28.

bioMérieux will be located at booth No.6634.

"We look forward to engaging with existing and new customers at SupplySide West and showcasing our innovative nutraceutical testing solutions," said Ben Pascal, chief business officer with Invisible Sentinel, a bioMérieux company. "There is an industry notion that rapid testing is not an acceptable equivalent to USP methods, and we'd like to show the industry how bioMérieux has revolutionized rapid testing methods, paving the way for the future of testing for nutraceuticals."

One of the many solutions bioMérieux will feature at SupplySide West 2021 is its newly released GENE-UP NUTRAPLEX PRO Assay, which was recently awarded the first-ever AOAC® Research Institute Performance Tested MethodsSM approval (PTM 082103) approval for multiplex USP pathogen detection and PCR-based culture confirmation in nutraceutical products. With this certification, GENE-UP NUTRAPLEX PRO outperformed both FDA BAM and USP <2022>.

The GENE-UP NUTRAPLEX PRO is a multiplex assay that simultaneously detects Escherichia coli, Salmonella spp. and Staphylococcus aureus from a single universal enrichment in 24 hours. GENE-UP NUTRAPLEX PRO meets the needs of USP <2022> across a wide variety of challenging nutraceutical matrices, while improving overall efficiencies.

As a leading innovator in nutraceuticals testing, bioMérieux helps customers go from complex testing methods to simple rapid methods through its full suite of testing solutions, including the GENE-UP NUTRAPLEX PRO. Other solutions include the automated enumeration TEMPO® system and immunoassay pathogen screening VIDAS® system, among many others that can bring both precision and speed in testing functional foods and beverages as well as dietary, herbal and protein supplements and vitamins.

While the size of the U.S. nutraceuticals market is projected to reach around $120 million by the end of 2027, bioMérieux is revolutionizing previous testing methods and outperforms traditional USP culture methods. This is a paradigm shift in microbial quality testing for nutraceuticals. There is a faster, alternative testing method allowed by USP methodology, the industry standard for nutraceutical microbiology safety and quality testing. Traditional culture-based methods and available singleplex molecular assays are cost and labor prohibitive with less accuracy across the diverse range of nutraceutical matrices. Previous and widely accepted methods of testing nutraceuticals are now being met with an entirely new way to test via bioMérieux's breakthrough technology and rapid testing.

SupplySide West attendees will have an opportunity to meet firsthand with bioMérieux's team of experts who can help advise and provide education on the next generation of testing solutions for those looking to simplify, streamline and bring greater efficiency to nutraceuticals testing.

For more information, please visit biomerieux-usa.com/food-safety.

About Biomérieux

Pioneering Diagnostics

A world leader in the field of in vitro diagnostics for over 55 years, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2020, revenues reached €3.1 billion, with over 90% of international sales (outside of France).

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.

bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM - ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP

Corporate website: www.biomerieux.com

CONTACTS

Durée & Company, Inc.:
954.723.9350
bmxpr@dureeandcompany.com

bioMérieux
Joy Dell'Aringa
224-213-1756
joy.dellaringa@biomerieux.com

bioMérieux
Olivia Seward
+33 (0) 668740207
olivia.seward@biomerieux.com

###

SOURCE: bioMérieux



View source version on accesswire.com:
https://www.accesswire.com/666689/bioMerieux-to-Exhibit-at-SupplySide-West-2021-at-Mandalay-Bay-in-Las-Vegas-Oct-25-28-2021

© 2021 ACCESS Newswire
Die USA haben fertig! 5 Aktien für den China-Boom
Die Finanzwelt ist im Umbruch! Nach Jahren der Dominanz erschüttert Donald Trumps erratische Wirtschaftspolitik das Fundament des amerikanischen Kapitalismus. Handelskriege, Rekordzölle und politische Isolation haben eine Kapitalflucht historischen Ausmaßes ausgelöst.

Milliarden strömen aus den USA – und suchen neue, lukrative Ziele. Und genau hier kommt China ins Spiel. Trotz aller Spannungen wächst die chinesische Wirtschaft dynamisch weiter, Innovation und Digitalisierung treiben die Märkte an.

Im kostenlosen Spezialreport stellen wir Ihnen 5 Aktien aus China vor, die vom US-Niedergang profitieren und das Potenzial haben, den Markt regelrecht zu überflügeln. Wer jetzt klug investiert, sichert sich den Zugang zu den neuen Wachstums-Champions von morgen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche 5 Aktien die Konkurrenz aus den USA outperformen dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.